Terumo aortic Treo装置用于开窗腔内动脉瘤修复的初步经验
本研究基于前瞻性IDE临床试验,报告了46例短颈或近肾腹主动脉瘤患者使用Terumo aortic Treo装置行开窗腔内修复的初步经验。技术成功率达98%(45/46),仅1例肾动脉未保留,Treo的移植物修改时间(43分钟)显著短于其他装置,提示该装置高效且技术成功率高。
要点
- Treo装置行FEVAR技术成功率为98%,仅1例肾动脉未成功保留。
- Treo移植物修改时间43分钟,显著短于Cook Zenith(55分钟)和Medtronic Endurant(54分钟)。
- 平均随访598天,18例内漏(17例II型,1例III型),1例III型需再干预。
核心结论
- Treo装置用于FEVAR高效且技术成功率高,即使在高复杂度病例中手术和透视时间也较低,已成为该机构多数患者的首选技术。
主要发现
- 患者平均年龄75岁,男性70%,高血压74%,高脂血症83%,冠心病33%,COPD 33%。
- 平均动脉瘤大小66 mm,术前平均肾下颈长5 mm,最终密封区长度45 mm。
- 平均住院和ICU停留时间分别为2.4天和1.5天。
- 共创建129个开窗(44个SMA,85个肾动脉),平均每例2.8个开窗。
- 技术成功率为98%(45/46),平均随访598天,18例内漏(17例II型,1例III型),1例III型需再干预。
关键数值与推荐
- 技术成功定义为装置成功植入且所有目标血管保留,本组为98%(45/46)。
- Treo移植物修改时间43分钟,显著短于Cook Zenith(55分钟)和Medtronic Endurant(54分钟),P < .0001。
临床怎么用
- 对于短颈或近肾腹主动脉瘤患者,Treo装置行FEVAR技术成功率高,手术效率高,可作为首选技术之一。
局限性
- 单中心初步经验,样本量46例,随访时间平均598天,缺乏与其他装置的随机对照比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The Terumo aortic (TA) Treo device (Terumo, Somerset, NJ) is an endograft with unique features that lends itself to fenestrated endovascular aneurysm repair (FEVAR), including a low device profile, a wide amplitude stent design, and an increased interstent distance. We have described our initial experience with the Treo device for FEVAR to treat short neck and juxtarenal abdominal aortic aneurysms. METHODS: As part of an ongoing physician-sponsored investigational device exemption clinical trial (ClinicalTrials.gov identifier, NCT01538056), subjects were prospectively enrolled and underwent elective FEVAR using a variety of devices. Demographic and procedural details were collected. The data from subjects treated specifically with the Treo device from November 3, 2016 to May 2, 2019 were collected and analyzed. RESULTS: Of a cohort of 161 patients who had undergone elective FEVAR, 46 had been treated with the TA Treo device. Most patients were men (70%), with a mean age of 75 years and high rates of hypertension (74%), hyperlipidemia (83%), coronary artery disease (33%), and chronic obstructive pulmonary disease (33%). The mean aneurysm size was 66 mm, the mean preoperative infrarenal neck length was 5 mm, and the mean final seal zone length was 45 mm. The average hospital and intensive care unit lengths of stay were 2.4 and 1.5 days, respectively. A total of 129 fenestrations were created for 44 superior mesenteric and 85 renal arteries (2.8 fenestrations per patient). Technical success, defined as successful implantation of the device with all target vessels preserved, was 98% (45 of 46), with only one renal artery not successfully preserved. The mean follow-up period was 598 days. During the study period, 18 endoleaks were detected (17 type II and 1 type III), with one patient with a type III endoleak requiring reintervention. Three subjects had died within 30 days, one of intracranial hemorrhage, one of respiratory failure, and one of ischemic colitis. The graft modification times for the TA Treo were significantly shorter (43 minutes) than those for other commercially available devices (Cook Zenith, 55 minutes; Medtronic Endurant, 54 minutes; P < .0001). CONCLUSIONS: Our institution has reported exclusive worldwide experience using the TA Treo device for FEVAR. This device provides for a highly efficient and technically successful procedure for most patients. The procedural and fluoroscopy times were low even in the setting of high complexity. The technical success rates and simplification of the FEVAR procedure have made this approach a preferred technique for most patients at our institution.
引用
- Hemingway JF, Starnes BW, Kline BR, et al. Initial experience with the Terumo aortic Treo device for fenestrated endovascular aneurysm repair. J Vasc Surg. 2021. PMID: 33592291. doi:10.1016/j.jvs.2021.01.042
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。